KEZAR LIFE SCIENCES INC (KZR)

Company Profile

Kezar Life Sciences Inc is a US-based company operating in Biotechnology industry. The company is headquartered in South San Francisco, California and currently employs 58 full-time employees. The company went IPO on 2018-06-21. Kezar Life Sciences, Inc. is a clinical-stage biopharmaceutical company focused on discovering and developing small molecule therapeutics to treat unmet needs in immune-mediated diseases and cancer. The firm's lead product candidate, zetomipzomib, is a first-in-class selective immunoproteasome inhibitor that has completed Phase Ia testing in healthy volunteers and a Phase Ib/IIa clinical trial in patients with systemic lupus erythematosus (SLE), with or without lupus nephritis (LN). Its oncology product candidate, KZR-261, is a small molecule agent, targeting the Sec61 translocon and protein secretion pathway, being studied in an open-label Phase I clinical trial designed to evaluate safety and tolerability, pharmacokinetics and pharmacodynamics, as well to explore preliminary anti-tumor activity. This study is being conducted in two parts: dose escalation in patients with locally advanced or metastatic solid malignancies, and dose expansion in patients with selected tumor types.

Company Info

KEZAR LIFE SCIENCES INC

4000 Shoreline Ct Ste 300

South San Francisco CALIFORNIA 94080

P: 16508225600

CEO: John Fowler

Employees: 58

Website: https://kezarlifesciences.com/